UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials

The Journal of dermatological treatment, 2022-01, Vol.33 (1), p.219-228

2022

Volltextzugriff (PDF)

Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis

British journal of dermatology (1951), 2010-06, Vol.162 (6), p.1349-1358

2010

Volltextzugriff (PDF)

An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals

British journal of dermatology (1951), 2013-02, Vol.168 (2), p.374-380

2013

Volltextzugriff (PDF)

Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)

British journal of dermatology (1951), 2021-08, Vol.185 (2), p.323-334

2021

Volltextzugriff (PDF)

Outcomes of pregnancies from the tildrakizumab phase I–III clinical development programme

British journal of dermatology (1951), 2020-07, Vol.183 (1), p.184-186

2020

Volltextzugriff (PDF)

Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate‐to‐severe chronic plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, 2020-07, Vol.34 (7), p.1500-1509

2020

Volltextzugriff (PDF)

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2

Journal of the European Academy of Dermatology and Venereology, 2022-10, Vol.36 (10), p.1774-1783

2022

Volltextzugriff (PDF)

Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study

Journal of the European Academy of Dermatology and Venereology, 2020-12, Vol.34 (12), p.e803-e805

2020

Volltextzugriff (PDF)

Incidence of cardiovascular events among tildrakizumab‐treated patients with moderate‐to‐severe plaque psoriasis: pooled data from three large randomised clinical trials

Journal of the European Academy of Dermatology and Venereology, 2020-01, Vol.34 (1), p.e21-e24

2020

Volltextzugriff (PDF)

Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: Letter to the Editor

Journal of the European Academy of Dermatology and Venereology, 2019-10, Vol.33 (10), p.e350-e352

2019

Volltextzugriff (PDF)

Evidence for an Interferon-Inducible Gene, Ifi202, in the Susceptibility to Systemic Lupus

Immunity (Cambridge, Mass.), 2001-09, Vol.15 (3), p.435-443

2001

Volltextzugriff (PDF)

Genetic linkage of IgG autoantibody production in relation to lupus nephritis in New Zealand hybrid mice

The Journal of clinical investigation, 1996-10, Vol.98 (8), p.1762-1772

1996

Volltextzugriff (PDF)

Aging-Dependent Exclusion of Antigen-Inexperienced Cells from the Peripheral B Cell Repertoire

The Journal of immunology (1950), 2002-05, Vol.168 (10), p.5014-5023

2002

Volltextzugriff (PDF)

Control of Separate Pathogenic Autoantibody Responses Marks MHC Gene Contributions to Murine Lupus

Proceedings of the National Academy of Sciences - PNAS, 1999-07, Vol.96 (14), p.8098-8103

1999

Volltextzugriff (PDF)

Effect of Genetic Background on the Contribution of New Zealand Black Loci to Autoimmune Lupus Nephritis

Proceedings of the National Academy of Sciences - PNAS, 1996-12, Vol.93 (26), p.15164-15168

1996

Volltextzugriff (PDF)

New Loci from New Zealand Black and New Zealand White on Chromosomes 4 and 12 Contribute to Lupus-Like Disease in the Context of BALB/c

The Journal of immunology (1950), 2004-04, Vol.172 (7), p.4609-4617

2004

Volltextzugriff (PDF)

Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis

Journal of the European Academy of Dermatology and Venereology, 2019-10, Vol.33 (10), p.e350-e352

2019

Volltextzugriff (PDF)

Control of multiple autoantibodies linked with a lupus nephritis susceptibility locus in New Zealand black mice

The Journal of immunology (1950), 1997-06, Vol.158 (11), p.5566-5574

1997

Volltextzugriff (PDF)

MHC-linked control of murine SLE

Current topics in microbiology and immunology, 1999, Vol.246, p.275

1999

Volltextzugriff (PDF)

A Novel Locus Regulates Both Retroviral Glycoprotein 70 and Anti-Glycoprotein 70 Antibody Production in New Zealand Mice When Crossed with BALB/c

The Journal of immunology (1950), 2004-04, Vol.172 (8), p.5078-5085

2004

Volltextzugriff (PDF)

Analysis of the New Zealand Black contribution to lupus-like renal disease. Multiple genes that operate in a threshold manner

The Journal of immunology (1950), 1995-03, Vol.154 (5), p.2441-2447

1995

Volltextzugriff (PDF)

Enhanced Susceptibility to Lupus Contributed from the Nonautoimmune C57BL/10, But Not C57BL/6, Genome

The Journal of immunology (1950), 2000-05, Vol.164 (10), p.5515-5521

2000

Volltextzugriff (PDF)

Purification of transfer factors

Molecular immunology, 1992-02, Vol.29 (2), p.167-182

1992

Volltextzugriff (PDF)

Analysis of MHC Class II Genes in the Susceptibility to Lupus in New Zealand Mice

The Journal of immunology (1950), 1999-03, Vol.162 (5), p.2623-2630

1999

Volltextzugriff (PDF)

EE291 Psoriasis-Related Work Productivity Improvement from a Phase 4 Real-World Study Interim Analysis of Tildrakizumab in Patients with Moderate to Severe Psoriasis

Value in health, 2022-07, Vol.25 (7), p.S390-S391

2022

Volltextzugriff (PDF)

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(104)
Mit Volltextzugriff
(91)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(45)
Life Sciences & Biomedicine
(43)
Animals
(29)
Mice
(28)
Immunology
(20)
Humans
(19)
Female
(18)
Dermatology
(14)
Male
(13)
Mice, Inbred C57bl
(13)
Mice, Inbred Nzb
(13)
Biological And Medical Sciences
(12)
Mice, Inbred Balb C
(11)
Crosses, Genetic
(10)
Lupus Erythematosus, Systemic - Genetics
(10)
Genetic Predisposition To Disease
(9)
Psoriasis - Drug Therapy
(9)
Autoantibodies - Biosynthesis
(8)
Lupus Erythematosus, Systemic - Immunology
(8)
Lupus Nephritis - Genetics
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials

Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis

An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals

Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)

Outcomes of pregnancies from the tildrakizumab phase I–III clinical development programme

Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate‐to‐severe chronic plaque psoriasis

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2

Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study

Incidence of cardiovascular events among tildrakizumab‐treated patients with moderate‐to‐severe plaque psoriasis: pooled data from three large randomised clinical trials

Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: Letter to the Editor

Evidence for an Interferon-Inducible Gene, Ifi202, in the Susceptibility to Systemic Lupus

Genetic linkage of IgG autoantibody production in relation to lupus nephritis in New Zealand hybrid mice

Aging-Dependent Exclusion of Antigen-Inexperienced Cells from the Peripheral B Cell Repertoire

Control of Separate Pathogenic Autoantibody Responses Marks MHC Gene Contributions to Murine Lupus

Effect of Genetic Background on the Contribution of New Zealand Black Loci to Autoimmune Lupus Nephritis

New Loci from New Zealand Black and New Zealand White on Chromosomes 4 and 12 Contribute to Lupus-Like Disease in the Context of BALB/c

Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis

Control of multiple autoantibodies linked with a lupus nephritis susceptibility locus in New Zealand black mice

MHC-linked control of murine SLE

A Novel Locus Regulates Both Retroviral Glycoprotein 70 and Anti-Glycoprotein 70 Antibody Production in New Zealand Mice When Crossed with BALB/c

Analysis of the New Zealand Black contribution to lupus-like renal disease. Multiple genes that operate in a threshold manner

Enhanced Susceptibility to Lupus Contributed from the Nonautoimmune C57BL/10, But Not C57BL/6, Genome

Purification of transfer factors

Analysis of MHC Class II Genes in the Susceptibility to Lupus in New Zealand Mice

EE291 Psoriasis-Related Work Productivity Improvement from a Phase 4 Real-World Study Interim Analysis of Tildrakizumab in Patients with Moderate to Severe Psoriasis

Suchergebnisse filtern